Discussion about this post

User's avatar
Michael Synan's avatar

Great insights as usual.

Expand full comment
David Brown's avatar

This post reminded me of this Ashleigh Brilliant Quote: “Somehow I reached excess without ever noticing when I was passing through satisfaction.”

One can learn a lot about GLP-1 agonists if one Googles 'GLP-1 agonist Endocannabinoid System'.

This is a good summary regarding endocannabinoid system function. "The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a balance in internal environment (temperature, mood, and immune system) and energy input and output in living, biological systems. In addition to regulating physiological processes, the ECS directly influences anxiety, feeding behaviour/appetite, emotional behaviour, depression, nervous functions, neurogenesis, neuroprotection, reward, cognition, learning, memory, pain sensation, fertility, pregnancy, and pre-and post-natal development. The ECS is also involved in several pathophysiological diseases such as cancer, cardiovascular diseases, and neurodegenerative diseases. In recent years, genetic and pharmacological manipulation of the ECS has gained significant interest in medicine, research, and drug discovery and development. The distribution of the components of the ECS system throughout the body, and the physiological/pathophysiological role of the ECS-signalling pathways in many diseases, all offer promising opportunities for the development of novel cannabinergic, cannabimimetic, and cannabinoid-based therapeutic drugs that genetically or pharmacologically modulate the ECS via inhibition of metabolic pathways and/or agonism or antagonism of the receptors of the ECS. This modulation results in the differential expression/activity of the components of the ECS that may be beneficial in the treatment of a number of diseases." https://www.mdpi.com/1422-0067/22/17/9472

Rather than just modulate different aspects of endocannabinoid system function with pharmaceuticals, to me it makes sense to rebalance the system by reducing arachidonic acid intake. Excerpt: "Excessive signaling of arachidonic acid (AA) metabolites has been associated with various chronic degenerative or autoimmune diseases, and intervention with the metabolism of AA is widely employed therapeutically in these afflictions. In essence, AA is the most biologically active unsaturated fatty acid in higher animals. Its concentration in membranes and its magnitude of effects depend on its amount, or that of its precursors and analogues, in the diet. The tendency of the field of nutrition to ignore the role of dietary AA will optimistically be reversed in the future." https://pubmed.ncbi.nlm.nih.gov/8642436/

It is not widely known that one reason why the Mediterranean style diet produces favorable results is because it doesn't contain a lot of arachidonic acid. According to Steve Blechman, "The Mediterranean diet is low in arachidonic acid and rich in healthy fats such as monounsaturated fats found in extra-virgin olive oil (EVOO), nuts and omega-3 fatty acids from fish, which has been shown to lower the risk of inflammation, heart disease, cancer, diabetes and obesity, and other degenerative diseases." https://advancedmolecularlabs.com/blogs/news/new-red-meat-study-controversy

Expand full comment
2 more comments...

No posts